Compositions and methods for treating pain and anxiety disorders

Abstract

Pain is often in one or more anatomical sites is the predominant complaint of subjects and is often severe enough to require medical or therapeutic intervention. In an aspect, the treatments disclosed herein affect the amount of AEA by altering FAAH expression in a bodily fluid of a subject having a pain and/or anxiety disorder. Treatment methodologies of this disclosure are characterized by a temporal reduction in the expression of the FAAH gene and secondarily a decreased expression of the FAAH enzyme or both as mediated by gene expression modifiers (GEMs).

Dependencies are inferred from the claim text.